IONS ▲ +3.3% - Ionis Pharmaceuticals, Inc. $IONS Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS Ionis Pharmaceuticals shares rose 3.3% following the company's announcement of positive Phase 3 topline results for ulefnersen in the FUSION study, a trial of the investigational treatment for FUS-ALS (frontotemporal ALS caused by FUS gene mutations). The positive data represents a significant milestone toward potential regulatory approval of what would be the first disease-modifying therapy for this rare neurological condition. 22-SEP-2026 08:00 AM ET